验证数据展示
经过测试的应用
Positive FC (Intra) detected in | human PBMCs |
推荐稀释比
应用 | 推荐稀释比 |
---|---|
This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 μl per 10^6 cells in a 100 µl suspension or 5 μl per 100 µl of whole blood. | |
Sample-dependent, Check data in validation data gallery. |
发表文章中的应用
FC | See 1 publications below |
产品信息
FITC-65202 targets CD68 in FC (Intra) applications and shows reactivity with human samples.
经测试应用 | FC (Intra) Application Description |
文献引用应用 | FC, FC (Intra) |
经测试反应性 | human |
文献引用反应性 | human |
免疫原 | Lysosomal fraction of human alveolar macrophages 种属同源性预测 |
宿主/亚型 | Mouse / IgG1, kappa |
抗体类别 | Monoclonal |
产品类型 | Antibody |
全称 | CD68 molecule |
别名 | SCARD1, Macrosialin, KP1, GP110, CD68 molecule |
计算分子量 | 37 kDa |
GenBank蛋白编号 | BC015557 |
基因名称 | CD68 |
Gene ID (NCBI) | 968 |
RRID | AB_2924132 |
偶联类型 | FITC Plus Fluorescent Dye |
最大激发/发射波长 | 495 nm / 524 nm |
形式 | Liquid |
纯化方式 | Protein G purification |
UNIPROT ID | P34810 |
储存缓冲液 | PBS with 0.09% sodium azide and 0.5% BSA , pH 7.3 |
储存条件 | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
背景介绍
CD68 is a type I transmembrane glycoprotein that is highly expressed by human monocytes and tissue macrophages. It belongs to the lysosomal/endosomal-associated membrane glycoprotein (LAMP) family and primarily localizes to lysosomes and endosomes with a smaller fraction circulating to the cell surface. CD68 is also a member of the scavenger receptor family. It may play a role in phagocytic activities of tissue macrophages.
实验方案
Product Specific Protocols | |
---|---|
FC protocol for FITC Plus CD68 antibody FITC-65202 | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
发表文章
Species | Application | Title |
---|---|---|
Front Bioeng Biotechnol Evaluation of nanoparticle albumin-bound paclitaxel loaded macrophages for glioblastoma treatment based on a microfluidic chip | ||
Int Immunopharmacol FOXF2 suppressed esophageal squamous cell carcinoma by reducing M2 TAMs via modulating RNF144A-FTO axis |